NASDAQ:AUTL Autolus Therapeutics - AUTL Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Autolus Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. $2.15 +0.16 (+8.04%) (As of 01/31/2023 05:32 PM ET) Add Compare Share Share Today's Range$1.96▼$2.1550-Day Range$1.74▼$3.2552-Week Range$1.60▼$5.04Volume1.26 million shsAverage Volume532,955 shsMarket Capitalization$372.08 millionP/E RatioN/ADividend YieldN/APrice Target$9.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Autolus Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside338.4% Upside$9.00 Price TargetShort InterestHealthy0.29% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.44Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.70) to ($1.44) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.77 out of 5 starsMedical Sector61st out of 1,055 stocksBiological Products, Except Diagnostic Industry13th out of 170 stocks 3.5 Analyst's Opinion Consensus RatingAutolus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.00, Autolus Therapeutics has a forecasted upside of 338.4% from its current price of $2.05.Amount of Analyst CoverageAutolus Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.29% of the outstanding shares of Autolus Therapeutics have been sold short.Short Interest Ratio / Days to CoverAutolus Therapeutics has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Autolus Therapeutics has recently decreased by 24.30%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAutolus Therapeutics does not currently pay a dividend.Dividend GrowthAutolus Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AUTL. Previous Next 3.6 News and Social Media Coverage News SentimentAutolus Therapeutics has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Autolus Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for AUTL on MarketBeat in the last 30 days. This is a decrease of -89% compared to the previous 30 days.MarketBeat Follows4 people have added Autolus Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Autolus Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders25.70% of the stock of Autolus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions70.06% of the stock of Autolus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Autolus Therapeutics are expected to grow in the coming year, from ($1.70) to ($1.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Autolus Therapeutics is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Autolus Therapeutics is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAutolus Therapeutics has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Autolus Therapeutics (NASDAQ:AUTL) StockAutolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. The company was founded by Martin Pule in September 2014 and is headquartered in London, the United Kingdom.Read More Receive AUTL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Autolus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AUTL Stock News HeadlinesJanuary 20, 2023 | finance.yahoo.comAutolus Therapeutics announces Board changesDecember 26, 2022 | finance.yahoo.comIndividual investors account for 36% of Autolus Therapeutics plc's (NASDAQ:AUTL) ownership, while private equity firms account for 32%January 31, 2023 | Investing Trends (Ad)Without Graphite, There Would Be ZERO EV Batteries!Investors constantly hear that lithium is the key to powering the transition to green energy. Truth is, today's EV batteries contain more graphite in volume than any other essential ingredients.December 21, 2022 | finance.yahoo.comAutolus Announces Partial Exercise of Underwriters' Option to Purchase Additional ADSsDecember 12, 2022 | finance.yahoo.comAutolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022December 9, 2022 | marketwatch.comAutolus Therapeutics ADSs Sink to New Depths After Dilutive Offering >AUTLDecember 9, 2022 | finance.yahoo.comAutolus Therapeutics' Leukemia Trial Meets Primary Goal Of Remission Rate, Shares Fall After $150M Capital RaiseDecember 9, 2022 | finance.yahoo.comWhy Autolus Therapeutics Stock Is Crashing TodayJanuary 31, 2023 | Investing Trends (Ad)Without Graphite, There Would Be ZERO EV Batteries!Investors constantly hear that lithium is the key to powering the transition to green energy. Truth is, today's EV batteries contain more graphite in volume than any other essential ingredients.December 9, 2022 | marketwatch.comAutolus Therapeutics ADSs Tumble Premarket on Public Offering >AUTLDecember 9, 2022 | finance.yahoo.comAutolus Therapeutics announces pivotal Phase 2 FELIX clinical trial has met primary endpoint at interim analysisDecember 9, 2022 | markets.businessinsider.comSyncona: Autolus' FELIX Trial Of Obe-cel Meets Primary EndpointDecember 9, 2022 | markets.businessinsider.comAutolus Therapeutics Prices Public Offering Of 75 Mln ADSsDecember 8, 2022 | markets.businessinsider.comMizuho Securities Keeps Their Buy Rating on Autolus Therapeutics (AUTL)December 8, 2022 | finance.yahoo.comAutolus Therapeutics to Receive $70 Million in Milestone Payments from Blackstone Life SciencesNovember 30, 2022 | finance.yahoo.comAutolus Therapeutics announces handover of first clean rooms of new Stevenage, UK, manufacturing facilityNovember 29, 2022 | finance.yahoo.comAutolus Therapeutics plc's (NASDAQ:AUTL) Intrinsic Value Is Potentially 21% Below Its Share PriceNovember 9, 2022 | finance.yahoo.comAutolus Therapeutics Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS In LineNovember 5, 2022 | finance.yahoo.comShareholders in Autolus Therapeutics (NASDAQ:AUTL) have lost 81%, as stock drops 22% this past weekNovember 3, 2022 | msn.comAutolus Therapeutics: Q3 Earnings InsightsNovember 3, 2022 | finance.yahoo.comAutolus Therapeutics to Present Three Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022November 3, 2022 | finance.yahoo.comAutolus Therapeutics Reports Third Quarter 2022 Financial Results and Operational ProgressOctober 21, 2022 | finance.yahoo.comAutolus Therapeutics to Report Third Quarter 2022 Financial Results on November 3, 2022October 5, 2022 | msn.com11 Health Care Stocks Moving In Wednesday's Pre-Market SessionOctober 4, 2022 | finance.yahoo.comAutolus Therapeutics Stock Jumps After Bristol Myers Pact For Safety Switch SystemOctober 4, 2022 | marketwatch.comAutolus Therapeutics Shares Jump After Cancer-Collaboration Agreement with Bristol MyersOctober 4, 2022 | seekingalpha.comAutolus stock rises on Bristol Myers contract for use of safety switch with cell therapiesSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive AUTL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Autolus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AUTL Company Calendar Last Earnings11/03/2022Today1/31/2023Next Earnings (Estimated)3/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AUTL CUSIPN/A CIK1730463 Webwww.autolus.com Phone442038296230FaxN/AEmployees324Year FoundedN/APrice Target and Rating Average Stock Price Forecast$9.00 High Stock Price Forecast$11.00 Low Stock Price Forecast$7.00 Forecasted Upside/Downside+318.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.85) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-142,100,000.00 Net MarginsN/A Pretax Margin-6,969.80% Return on Equity-68.14% Return on Assets-48.56% Debt Debt-to-Equity Ratio0.07 Current Ratio5.47 Quick Ratio5.47 Sales & Book Value Annual Sales$2.33 million Price / Sales159.69 Cash FlowN/A Price / Cash FlowN/A Book Value$3.45 per share Price / Book0.62Miscellaneous Outstanding Shares173,060,000Free Float128,583,000Market Cap$372.08 million OptionableNot Optionable Beta1.57 Key ExecutivesChristian Martin ItinChief Executive Officer & DirectorChristopher VannChief Operating Officer & Senior Vice PresidentLucinda CrabtreeChief Financial OfficerMartin PuléChief Scientific Officer & Senior Vice PresidentDavid BrochuChief Technical Officer & Senior Vice PresidentKey CompetitorsMonte Rosa TherapeuticsNASDAQ:GLUECabaletta BioNASDAQ:CABAMeiraGTxNASDAQ:MGTXVoyager TherapeuticsNASDAQ:VYGRAdaptimmune TherapeuticsNASDAQ:ADAPView All CompetitorsInsiders & InstitutionsPendal Group LtdBought 362,634 shares on 1/19/2023Ownership: 1.002%Alphabet Inc.Bought 698,262 shares on 11/16/2022Ownership: 0.766%TFG Asset Management GP LtdBought 19,968 shares on 11/15/2022Ownership: 3.335%BlackRock Inc.Sold 20,991 shares on 11/15/2022Ownership: 0.490%Caxton Associates LPSold 5,200 shares on 11/15/2022Ownership: 0.092%View All Institutional Transactions AUTL Stock - Frequently Asked Questions Should I buy or sell Autolus Therapeutics stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Autolus Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AUTL shares. View AUTL analyst ratings or view top-rated stocks. What is Autolus Therapeutics' stock price forecast for 2023? 3 brokers have issued 1 year target prices for Autolus Therapeutics' stock. Their AUTL share price forecasts range from $7.00 to $11.00. On average, they expect the company's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 347.8% from the stock's current price. View analysts price targets for AUTL or view top-rated stocks among Wall Street analysts. How have AUTL shares performed in 2023? Autolus Therapeutics' stock was trading at $1.90 at the beginning of 2023. Since then, AUTL shares have increased by 5.8% and is now trading at $2.01. View the best growth stocks for 2023 here. Are investors shorting Autolus Therapeutics? Autolus Therapeutics saw a decline in short interest in the month of January. As of January 15th, there was short interest totaling 500,400 shares, a decline of 24.3% from the December 31st total of 661,000 shares. Based on an average trading volume of 560,400 shares, the days-to-cover ratio is currently 0.9 days. View Autolus Therapeutics' Short Interest. When is Autolus Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023. View our AUTL earnings forecast. How were Autolus Therapeutics' earnings last quarter? Autolus Therapeutics plc (NASDAQ:AUTL) issued its quarterly earnings data on Thursday, November, 3rd. The company reported ($0.47) earnings per share for the quarter, missing analysts' consensus estimates of ($0.46) by $0.01. The business had revenue of $2.37 million for the quarter, compared to analysts' expectations of $0.30 million. What other stocks do shareholders of Autolus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Autolus Therapeutics investors own include Sorrento Therapeutics (SRNE), CRISPR Therapeutics (CRSP), VBI Vaccines (VBIV), GW Pharmaceuticals (GWPH), ImmunoGen (IMGN), Teva Pharmaceutical Industries (TEVA), TG Therapeutics (TGTX), AbbVie (ABBV), Adaptimmune Therapeutics (ADAP) and Advanced Micro Devices (AMD). When did Autolus Therapeutics IPO? (AUTL) raised $125 million in an initial public offering on Friday, June 22nd 2018. The company issued 7,800,000 shares at $15.00-$17.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and Wells Fargo Securities and William Blair were co-managers. What is Autolus Therapeutics' stock symbol? Autolus Therapeutics trades on the NASDAQ under the ticker symbol "AUTL." Who are Autolus Therapeutics' major shareholders? Autolus Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Pendal Group Ltd (1.00%) and Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of Autolus Therapeutics? Shares of AUTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Autolus Therapeutics' stock price today? One share of AUTL stock can currently be purchased for approximately $2.01. How much money does Autolus Therapeutics make? Autolus Therapeutics (NASDAQ:AUTL) has a market capitalization of $347.85 million and generates $2.33 million in revenue each year. The company earns $-142,100,000.00 in net income (profit) each year or ($1.85) on an earnings per share basis. How many employees does Autolus Therapeutics have? The company employs 324 workers across the globe. How can I contact Autolus Therapeutics? Autolus Therapeutics' mailing address is FOREST HOUSE 58 WOOD LANE WHITE CITY, LONDON X0, W12 7RZ. The official website for the company is www.autolus.com. The company can be reached via phone at 442038296230 or via email at ir@autolus.com. This page (NASDAQ:AUTL) was last updated on 1/31/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.